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Abstract 
Antibody Drug Conjugates (ADCs) represent a rapidly growing and extensively potent class of 
pharmaceuticals that utilize antibodies to deliver toxic chemicals directly to tumors and other 
dangerous cells while avoiding healthy tissues. This technology is based on the controlled yet 
spontaneous release of a drug compound via the domino-like cascade effect of the self-
immolative spacer system p-aminobenzyl alcohol (PABOH). This report seeks to investigate the 
effects that various PABOH analogues have on the kinetics of spacer degradation, in an effort to 
optimize the efficiency of the ADC in a therapeutic context. 
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1. Introduction 
Antibody Drug Conjugates (ADCs) are a promising new class of pharmaceuticals that unites the 
realms of powerful antibody technology and small molecule cytotoxic drugs. By linking a drug 
molecule to a carrier antibody, it is possible to combine the specificity and targeting power of 
antibodies with the high potency of otherwise toxic drug molecules. Antibodies are biomolecules 
that are highly targeted to specific proteins expressed on the surface of cells, called antigens. 
These protein targets can be carefully selected to guide antibodies in distinguishing between 
healthy and cancerous cells. With this technology, potent drugs with an established mechanism 
and therapeutical index are delivered directly to the target cell, resulting in not only increased 
efficacy, but also a marked decrease in harmful side effects.
1
 The power and potential of this 
technology was validated in the 2009 phase I trials of brentuximab vedotin, the first FDA 
approved ADC, which boasted a "52% overall response rate in relapsed Hodgkin's lymphoma, 
with minimal toxicity."
2 
This promising study is a result of decades of research to circumvent the inherent problems in the 
design of immunoconjugate drugs. The entire ADC complex must be soluble in blood plasma 
while retaining its structure and covalent link to the drug toxin, until the antibody has bound a 
malignant cell. A premature release of the drug would confer no benefits over traditional drug 
                                                          
1 Teicher, B. A., & Chari, R. V. (2011). Antibody Conjugate Therapeutics: Challenges and Potential. Clinical 
Cancer Research, 17(20), 6389-6397. 
2 Beck, A., Haeuw, J. F., Wurch, T., Goetsch, L., Bally, C., Corvaia, N. (2010). The Next Generation of 
Antibody-drug Conjugates Comes of Age. Discovery Medicine, 10(53), 329-339. 
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approaches or antibody-only therapies. It is also imperative that this bond can only be cleaved 
upon internalization by the cell, or the ADC complex would render the drug inactive.
3
 These 
concerns led to the design of synthetic linkers and self-immolative spacers that release the toxin 
in a controlled and predictable manner.
1,4
 Such technologies have been used to create potent, 
robust medicines with half-lives spanning over days or weeks, resulting in less frequency of 
administration and an increased quality of life for patients.
5
  
                                                          
3 Safavy, A., Georg, G. I., Vander Velde, D., Raisch, K. P., Safavy, K., Carpenter, M., Wang, W., Bonner, J. A., 
Khazaeli, M. B., Buchsbaum, D. J. (2004). Site-Specifically Traced Drug Release and Biodistribution of a 
Paclitaxel-Antibody Conjugate toward Improvement of the Linker Structure. Bioconjugate Chemistry, 15(6), 
1264-1274. 
4 Senter, P. D., & Sievers, E. L. (2012). The discovery and development of brentuximab vedotin for use in 
relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnology, 30(7), 631-
637. 
5 Carter, P. J. (2006). Potent antibody therapeutics by design. Nature Reviews Immunology, 6, 343-357. 
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2. Background 
Interest in the targeted delivery of drugs to specific harmful cells can be traced back as far as a 
century to Paul Ehrlich, a German immunologist who proposed the idea of such a "magic bullet" 
therapy.
4
 Animal models of the first ADC-like structures appeared in literature during the 
1960's.
2
 However, it wasn't until the development of the monoclonal, antigen-specific antibody 
in 1975 that clinical applications of ADCs became feasible.
4
 Since then, much focus of ADC 
research has been concentrated on manipulating and optimizing the antibody itself and ensuring 
uniformity and reproducibility in the drug linkages.
5
 We focus here, instead, on the development 
of a linker system with ideal kinetics, specifically at the point where the drug molecule is 
released from the complex. 
The structure of our antibody drug conjugate system is based on that of brentuximab vedotin, the 
only ADC medication currently approved by the FDA, shown below. 
 
Figure 1: Structure of brentuximab vedotin (Adcetris)
4
 
4 
 
 Created by Seattle Genetics and marketed as Adcetris, it was granted accelerated approval by 
the FDA in August 2011 for the treatment of relapsing Hodgkin lymphoma and anaplastic large 
cell lymphoma (ALCL). Adcetris quickly gained notoriety as the first treatment approved for 
Hodgkin lymphoma in over three decades. The structure of brentuximab vedotin consists of a 
monoclonal IgG antibody, followed by a stable yet self-degradative linkage, and finally the 
tubulin-inhibiting drug monomethyl auristatin E (MMAE). In a phase II clinical trial of this 
medicine, a 75% overall response rate (ORR) was observed in patients with Hodgkin lymphoma 
and 86% in ALCL , as compared to the unconjugated antibody which yielded 0% and 17% ORR, 
respectively. Remarkably, a reduction in tumor size was observed in 94% of Hodgkin lymphoma 
patients.
4 
Each antibody in a dose of Adcetris has an average of four drug molecules conjugated to its 
surface. A significant focus of ADC development has been on maximizing the amount of active 
drug delivered to the cell per antibody. The importance of this is demonstrated below in Figure 2, 
which outlines the six key steps in the ADC mechanism: reaching the target cell, binding it, 
internalization by the cell, cleavage of the drug molecule, transportation of the drug, and finally 
the desired drug delivery. 
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Figure 2: Overview of primary reactions in ADC delivery
1
 
Assuming this to be a singly linked drug complex and estimating that each of these six events 
occurs at 50% efficiency, only 1.56% of the active drug will reach its target.
1
  
ADCs with a larger number of drug linkages have also been investigated, but with a documented 
loss in potency and circulation time due to the likelihood of precipitation of the hydrophobic 
drug molecules.
3,4
 Early ADC models employed abundant lysine residues on the surface of the 
IgG antibody to covalently link toxins, but this resulted in a lack of homogeneity and hyper-
conjugated antibodies. With about 90 lysine molecules expressed on the antibody's surface, it 
was also difficult to prevent the drugs from binding to residues important in antigen recognition. 
Attention then turned to conjugation onto the antibody's external cysteine molecules. Treatment 
of the antibody with mild reducing conditions afforded only eight possible drug bond locations, 
none of which were crucial in antibody-antigen interactions.
2
  
 The linker system of brentuximab vedotin (Figure 2) is bound to the antibody's cysteine residue 
via a thiol conjugation to a maleimide ring.
4
 This is a well characterized Michael-type addition 
6 
 
reaction generally known to be stable and spontaneous in blood plasma conditions.
6
 Adjacent to 
the maleimide is a 5 carbon n-alkyl chain that serves as an inert spacer between the antibody and 
the self immolative linker-drug complex. This prevents steric and electronic interference by the 
conjugated drug with the antibody's ability to recognize and bind the desired antigen.
4 
Bound to the alkyl chain is a dipeptide linkage of valine to citrulline, which marks the essential 
starting point for the controlled drug release. When the ADC binds to its antigen, it is 
internalized into the cell by a lysosome in a process known as receptor-mediated endycytosis.
4
 
Inside the harsh environment of the lysosome, the ADC encounters the proteolytic enzyme 
Cathepsin B, which selectively cleaves peptide bonds. This specific protease is expressed almost 
exclusively in all mammalian lysosomes and high levels of cytosolic Cathepsin B have been 
correlated with poor cancer prognoses.
7,8
 Earlier drug-conjugate techniques report using pH-
sensitive linkers to initiate the self immolization, but the enzyme-mediated approach ensures that 
the complex is inside the lysosome, and thus the intended cell, before degradation.
1 
 
                                                          
6 Baldwin, A. D., & Kiick, K. L. (2011). Tunable Degradation of Maleimide-Thiol Adducts in Reducing 
Environments. Bioconjugate Chemistry, 22, 1946-1953. 
7 Toki, B. E., Cerveny, C. G., Wahl, A. F., Senter, P. D. (2002). Protease-Mediated Fragmentation of p-
Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs. Journal of Organic Chemistry, 
67(6), 1866-1872. 
8 Dubowchik, G. M., & Firestone, R. A. (1998). Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of 
structural requirements for efficient release of doxorubicin. Bioorganic & Medicinal Chemistry Letters, 8, 3341-
3346. 
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Figure 3: Cathepsin B mediated cleavage and 1,6-elimination of PABOH
4,9
 
 
When Cathepsin B cleaves the dipeptide bond between valine and citrulline, electron density is 
forced into the subsequent benzylic derivative, driving the disassembly of the linker and the 
release of an active drug molecule (Figure 3A).
7
 This cyclic spacer is para-aminobenzyl alcohol, 
commonly known as PABOH, and was developed in 1981 by the Katzenellenbogen group of the 
University of Illinois as an addition to traditional linkers in prodrug technology.
9,10
 PABOH is 
one of the most frequently employed self immolative spacers.
7
 When electron density enters the 
already conjugated system, PABOH decomposes through a 1,6-elimination reaction known as 
                                                          
9 Carl, P. L., Chakravarty, P. K., Katzenellenbogen, J. A. (1981). A Novel Connector Linkage Applicable in 
Prodrug Design. Journal of Medicinal Chemistry, 24(5), 479-480. 
10 Erez, R., & Shabat, D. (2008). The azaquinone-methide elimination: comparison study of 1,6- and 1,4-
eliminations under physiological conditions. Organic & Biomolecular Chemistry, 6, 2669-2672. 
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para-azaquinone-methide elimination (Figure 3B). This decomposition results in the spontaneous 
release of CO2 and a quinone species for further catalysis, along with the active drug that can 
now function in the cell. There is also evidence that ortho analogues of PABOH can function 
similarly through a 1,4-elimination, though the 1,6-elimination may be slightly faster under 
physiological conditions
10
. Brief investigations into the kinetics of heterocyclic rings, such as 
pyridine, in an equivalent PABOH system have also been reported with similar success.
11
 
  
                                                          
11 Perry-Feigenbaum, R., Baran, P. S., Shabat, D. (2009). The pyridinone-methide elimination. Organic & 
Biomolecular Chemistry, 7, 4825-4828. 
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3. Results and Discussion 
The general procedure for the construction of our antibody drug conjugate was as follows: 
Figure 4: L-Alanine coupling and ethyl ester deprotection 
Compound 1, the N-terminal boc-protected L-Alanine, was coupled to a C-terminal ethyl ester-
protected L-Alanine via the coupling reagent HATU. This reaction proceeded quickly and with 
excellent yield (93%), to afford compound 2, the twice protected di-Alanine system, after silica 
gel chromatography. The presence of this product was determined by 
1
H NMR via the 
disappearance of the carboxylic acid peak 1H singlet at δ=12.5 ppm and the presence of the 
corresponding peaks for the ethyl-protected Alanine: a 3H triplet at δ=1.16 ppm and 2H 
quadruplet at δ=4.05 ppm indicating the ethyl ester, a 3H triplet marking the methyl group 
(which is no longer a quadruplet) at δ=1.37 ppm, a 1H multiplet at δ=4.0 ppm indicating the 
adjacent C-H proton, and finally the amine doublet signal at δ= 8.15 ppm, which integrated to 1H 
instead of 2H. (NMR 1) 
The twice protected di-Alanine system 2 then underwent saponification to remove the ethyl ester, 
via treatment with an excess of NaOH and then the subsequent adjustment to pH 4 with acetic 
acid. Product 3, the deprotected carboxylic acid, was isolated by column chromatography in fair 
yield (76%). Its structure was confirmed by 
1
H NMR by the disappearance of the ethyl ester 
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protons, the 3H triplet at δ=1.16 ppm and 2H quadruplet at δ=4.05 ppm, along with the 
reappearance of the carboxylic acid 1H singlet at δ=12.5 ppm. 
 
Figure 5: PABOH addition and carbamate introduction 
The carboxylic acid deprotected di-Alanine compound 3 was then treated with (4-amino-
phenyl)-methanol (PABOH) or a derivative thereof. In combination with the coupling reagent 
EEDQ, the amine group on PABOH added into the exposed carboxylic acid site of the dipeptide, 
yielding compound 4 after flash chromatography. This product was identified with 
1
H NMR by 
the benzylic and methanol protons of each PABOH derivative, in the case of (4-amino-phenyl)-
methanol as two 2H multiplets at 7.23 and 7.52 ppm, along with a 2H doublet at δ=4.43 ppm and 
an alcohol 1H triplet at δ=5.09 ppm, respectively, as well as ensuring the amine proton peak of 
PABOH at δ=9.87 integrated to 1H and not 2H.  
The PABOH derivatives employed in this experiment are shown below:  
 
Figure 6: PABOH and other derivatives of interest 
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The final component of the self-immolative spacer, the carbamate functionality, was installed 
onto compound 4 by a triethylamine-mediated reaction with bis-(4-nitrophenyl) carbonate. After 
a flash column, this afforded compound 5 (below) in excellent yield (94%). 
1
H NMR analysis 
confirmed the structure by the addition of two 2H benzylic multiplets at δ=7.57 and 8.31 ppm, as 
well as the disappearance of the alcohol triplet from PABOH at δ= 5.09. Consequentially, the 
adjacent methylene group 2H shifted from a doublet at δ=4.43 to a singlet at δ=5.25.  
 
Figure 7: Attachment of the drug molecule dexamethamine 
Commercial dexamethamine (6), the amine form of the common anti-inflammatory drug 
dexamethasone, was attached to compound 5 through a diisopropylethylamine-mediated 
addition. This resulted in compound 7 after silica gel chromatography, the structure of which was 
elucidated by 
1
H NMR. The compound was identified by the disappearance of the benzylic 2H 
multiplets (δ=7.57 and 8.31 ppm) from the carbonate 5, as well as the identification of the peaks 
corresponding with the drug molecule 6, where the amine proton signal shifted from 2H at 
δ=8.20 to 1H at δ=7.99. 
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Figure 8: Amination of commercial dexamethasone 
The amination of dexamethasone (8) to dexamethamine (6) was also performed in house 
according to the synthetic route above. A methylsulfonyl group was added to the terminal 
alcohol on compound 8 via a triethylamine-mediated reaction with methanesulfonyl chloride. 
This product 9 was attained via flash column separation and identified by 
1
H NMR by the 
disappearance of the drug's alcohol triplet around δ=4.90 ppm, the doublet to singlet 
transformation of the 2H adjacent to the alcohol near δ=4.70 ppm, and the addition of a 3H 
singlet signal at δ=3.40 ppm indicating the methylsulfonyl group. 
 The introduction of the essential nitrogen molecule to compound 9 was performed by a 
substitution reaction using sodium azide to yield product 10. This compound was recovered by 
flash chromatography and its structure was confirmed by 
1
H NMR which indicated that the 3H 
methyl peak from the methylsulfonyl group at δ=3.40 ppm had vanished. The azide group on 
compound 10 was then reduced to the free amine by a reaction with solid zinc and acetic acid, 
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completing the amination process, in 97% yield. The synthetic dexamethamine was cleaned by 
flash column and its structure was confirmed by 
1
H NMR via the appearance of a 2H broad 
singlet signal at δ=8.20 ppm, suggesting the terminal free amine. 
Figure 9: Deprotection and addition of a new protecting group 
Once the drug molecule had been attached, the final step was to cap the system in preparation for 
the assay. In a clinical setting, the molecule would be terminated with an n-alkyl maleimide as 
discussed earlier, to conjugate to the cysteine on the antibody. Here we experimented with 
different protecting groups in an effort to replicate the clinical setting without constructing the 
whole antibody linkage. Compound 7, the boc-protected ADC system, was submitted for the 
assay and also used as a gateway to two other submissions.  
Compound 7 was deprotected using trifluoroacetic acid, to yield the free amine form of the 
system 11 after treatment with sodium hydroxide. Acquired by column chromatography, its 
structure was confirmed by 
1
H NMR by the lack of the t-butyl 9H singlet at δ=1.49 ppm. 
Compound 11 was submitted to the assay, and further treated with benzyl carbonochloridate in a 
triethylamine-mediated reaction to install the CBZ protecting group. This was run through a flash 
14 
 
column and the structure of the resulting product 12 was elucidated by 
1
H NMR. This structure 
was identified by the benzylic protons of the CBZ, a broad 5H multiplet peak that appeared at 
7.32 ppm. 
This synthetic route produced nine compounds ready for a timed stability assay, shown below: 
 
Figure 10: Summary of the ADCs submitted for assay 
The basic idea of the assay is that a certain amount of the ADC molecule will be introduced to an 
environment of cell media, Cathepsin B, and a buffer to maintain the pH at physiological 
conditions. At specific time points, a sample will be taken and the amount of free drug in the 
mixture will be monitored. As a control, the ADC will also be exposed to either only the buffer 
15 
 
or cell culture media. Ideally, there will be no free drug in just the media or buffer environments, 
since it is important that the ADC remain intact until it reaches the the enzymatic lysosome of 
the cell. As time progresses in the Cathepsin B solution, we should see the amount of free drug 
increase and will be able to monitor the drug release kinetics of our novel ADC structures. 
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4. Experimental 
General Methods: The following procedures were based on experiments performed by chemists 
at Abbott Bioresearch Center. Reactions were carried out under nitrogen gas and monitored by 
thin-layer chromotography on silica coated glass plates and visualized under UV light at 254 nm 
as well as a potassium permanganate stain. Reactions were also monitored via LCMS in a 
gradient from 5 to 95% acetonitrile in ammonium acetate through a Halo C8 silica gel column. 
Removal of solvent was performed with a rotary evaporator under reduced pressure. Flash 
columns were run on pre-packed silica gel columns with an AnaLogix column machine, and the 
structures of the resulting products were elucidated via a 500 MHz Bruker NMR spectrometer. 
All chemical shifts in ppm are reported relative to TMS at 0.00 ppm and samples were scanned 
in deuterated DMSO. 
The descriptions that follow depict various scales of reactions and describe only the original 
PABOH derivative. However, these reactions have successfully been run on many scales with 
comparable yields, and can be used interchangeably with other PABOH derivatives so long as 
the ratio of reagents is maintained. 
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The coupling reagent HATU (2.211 g, 5.81 mmol) was combined with (1) N- terminal boc 
protected L-Alanine (1 g, 5.29 mmol) and C- terminal ethyl ester protected L-Alanine HCl 
(0.893 g, 5.81 mmol) in a 100 mL roundbottom flask. To this was added dichloromethane 
(DCM) (26.4 mL) and triethylamine (2.81 mL, 21.14 mmol), and the yellow solution was stirred 
at room temperature for one hour. It was then quenched with sodium bicarbonate and the product 
was extracted twice into DCM, dried over anhydrous sodium sulfate, and the solvent evaporated 
to give a yellow oil. This was dissolved in minimal DCM and loaded onto a silica flash column 
with a gradient from 0 to 60% ethyl acetate in heptane. This afforded compound 2, the di-
protected di-Alanine system (1.42 g, 93%).  
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Compound 2 (1 g, 3.41 mmol) was added to a 100 mL roundbottom and dissolved in 1,4-dioxane 
(17.43 mL). To this was added 1M sodium hydroxide (13.87 mL, 13.87 mmol) and the 
homogenous solution was stirred at room temperature for 1.5 hours. The organic solvent was 
removed by vacuum, leaving the aqueous layer which was then acidified to pH 4 with 10% citric 
acid. The product was then extracted twice with ethyl acetate and washed with brine. After 
drying over sodium sulfate and removing the solvent, the white solid compound 3 was recovered 
(0.682 g, 76%) 
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To a 150 mL roundbottom containing compound 3 (0.342 g, 1.314 mmol) was added equal parts 
DCM (3.28 mL) and methanol (3.28 mL) with stirring to dissolve the solid. PABOH (0.178 g, 
1.445 mmol) was added to the flask, followed by the coupling reagent EEDQ (0.357 g, 1.445 
mmol). The yellow homogenous solution was allowed to stir at room temperature overnight, 
after which the solvent was removed under vacuum to afford yellow crystals. These were 
dissolved in DCM, washed with water and brine, and the organic layer dried. The crude product 
was subject to a flash silica column in a gradient from 0 to 60% ethyl acetate in heptane to yield 
compound 4 (0.220 g, 46%). 
  
20 
 
 
Compound 4 (.220 g, 0.602 mmol) was dissolved in THF (5 mL) in a 25 mL roundbottom flask. 
To this was added bis(4-nitrophenyl) carbonate (0.201 g, 0.662 mmol) with stirring and 
triethylamine (0.084 mL, 0.602 mmol) which afforded a yellow homogenous solution. The 
vessel was left stirring at room temperature overnight. It was then quenched with water and 
extracted twice into DCM. This was washed with brine and dried over anhydrous sodium sulfate, 
then subjected to a flash column with a gradient from 0 to 60% ethyl acetate in heptane. The 
organic solvent was removed under vacuum to yield compound 5 (0.299 g, 94%). 
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Compound 5 (1 g, 1.885 mmol) and commercial dexamethamine HCl (0.812 g, 2.073 mmol) 
were dissolved in DMF (15 mL) at room temperature. To this was added n,n-
diisopropylethylamine (1.218 g, 9.42 mmol) and the reaction was allowed to stir. After one hour, 
another 0.120 g of the aminated drug were added to the solution to drive the reaction to 
completion. The solution was then partitioned between ethyl acetate and water, the organic layer 
washed with brine and dried over sodium sulfate, and solvent removed by vacuum. The crude 
solid was taken up in DCM and run through a flash silica column with a gradient over 0 to 10% 
methanol in DCM to give product 7 (1.348 g, 91%). 
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To aminate the commercially available drug, a solution of  compound 8, dexamethasone (2 g, 
5.10 mmol) in THF (20 mL) was stirred and cooled to 0° C. To this was added triethylamine 
(1.065 mL, 7.64 mmol) and dropwise methanesulfonyl chloride (0.477 mL, 6.12 mmol). A white 
solid was constantly present in the solution and the vessel was allowed to stir at room 
temperature for 2.5 hours. The solids were filtered out and the THF removed by vacuum, leaving 
a tan solid which was partitioned between ethyl acetate and water. The organic layer was washed 
with brine and dried over sodium sulfate and the solvent removed by evaporation to yield 
compound 9 (1.56 g, 65 %). 
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Compound 9 (1.551 g, 3.30 mmol) was dissolved in DMSO (13 mL) and sodium azide (0.429 g, 
6.59 mmol) was introduced. The solution was stirred at 50° C for 45 minutes as the solution 
progressed to a deep orange color. The solution was cooled to room temperature and poured into 
50 mL of an ice and water mix to afford a bright yellow precipitate. The solid was filtered, 
dissolved in THF, washed with brine, dried over sodium sulfate, and concentrated by evaporation 
to yield 1.577 g of an amber oil. This is above 100% yield but the product, compound 10, was 
clean by NMR except for DMSO. 
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Compound 10 (1.376 g, 3.30 mmol) was dissolved in DCM (13.73 mL) and acetic acid (2.75 
mL) and cooled to 0° C. To this was added flakes of solid zinc metal (2.156 g, 33.0 mmol) and 
the reaction was stirred for two hours. The solids were filtered through filter paper and rinsed 
with methanol, and the filtrate was dried under vacuum. The crude product was partitioned 
between ethyl acetate and water, and the aqueous layer was adjusted to pH 10 with 10% 
Na2CO3. The product was extracted from here into ethyl acetate, which was dried over 
anhydrous magnesium sulfate, and evaporated to yield compound 6, the amine form of 
commercial dexamethasone (0.442 g, 33%).  
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Compound 7 (0.500 g, 0.639 mmol) was dissolved in DCM (15 mL) and cooled to 0° C. To this 
was added trifluoroacetic acid (0.492 mL, 6.39 mmol) dropwise. Upon full addition of the acid, 
the solution was allowed to equilibrate to room temperature and stir. This was then heated to 40° 
C and stirred for 5 hours. The solution was carefully quenched under proper ventilation with 
water, and the aqueous layer was basified dropwise with 1 N NaOH until no more solid 
production was observed. The solid was dissolved in diethyl ether, washed with brine, dried over 
sodium sulfate, and dried by vacuum. The crude product was treated with a flash column with a 
gradient of 50 to 100% of a 85:13.5:1.5 DCM:MeOH:NH4OH solution in DCM. This recovered 
compound 11 (.214 g, 49%). 
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Compound 11 (0.075 g, 0.099 mmol) was dissolved in DMF (1 mL). To this was added benzyl 
carbonochloridate (0.030 mL, 0.218 mmol) and triethylamine (0.053 mL, 0.395 mmol) and the 
reaction was allowed to stir as the vessel was heated to 45° C for three hours. The reaction was 
cooled to room temperature and quenched with sodium bicarbonate and extracted twice into 
DCM. This was washed with brine and dried over sodium sulfate with the solvent removed to 
yield a thick yellow oil. This was subjected to a flash column with a gradient of 60 to 100% ethyl 
acetate in heptane to yield Compound 12 (0.030 g, 37%). 
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